Pretreatment with Fucoidan from Fucus vesiculosus Protected against ConA-Induced Acute Liver Injury by Inhibiting Both Intrinsic and Extrinsic Apoptosis

Abstract

This study aimed to explore the effects of fucoidan from Fucus vesiculosus on concanavalin A (ConA)-induced acute liver injury in mice. Pretreatment with fucoidan protected liver function indicated by ALT, AST and histopathological changes by suppressing inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ). In addition, intrinsic and extrinsic apoptosis mediated by Bax, Bid, Bcl-2, Bcl-xL and Caspase 3, 8, and 9 were inhibited by fucoidan and the action was associated with the TRADD/TRAF2 and JAK2/STAT1 signal pathways. Our results demonstrated that fucoidan from Fucus vesiculosus alleviated ConA-induced acute liver injury via the inhibition of intrinsic and extrinsic apoptosis mediated by the TRADD/TRAF2 and JAK2/STAT1 pathways which were activated by TNF-α and IFN-γ. These findings could provide a potential powerful therapy for T cell-related hepatitis.

Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial

“…In our study, the grading of leukopenia, anemia, and thrombocytopenia was similar in both groups. Fucoidan has been reported to protect against liver injury and liver fibrosis in mice [38,39]. However, we did not observe this benefit with regard to chemotarget agents.…”

Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-β1/Smads and PI3K/Akt pathways

“…Further, we plan to do more studies on the treatment of quercetin for liver diseases, such as hepatitis 54 , 55 , inflammation associated hepatic diseases 56 , and hepatocellular carcinoma 57 – 59 . And we hope that quercetin can delay the progression of liver diseases, and cure them.…”

The 25(OH)Vitamin D Status Affected the Effectiveness of Oligo Fucoidan in Patients with Chronic Hepatitis B Virus Infection with Immune Tolerance Phase

“…Clinical studies have shown that oral fucoidan can reduce liver fibrosis and has anti-inflammatory effects in patients with non-alcoholic hepatitis (NAFLD) [17,19,21,22]. In an animal experiment, ALT and AST in the serum increased after ConA-induced liver inflammation in mice, and ALT and AST decreased in a dose-dependent manner after adding different concentrations of fucoidan [27]. Animal studies have also demonstrated that fucoidan reduces the titers of mouse liver virus B and HBsAg [28].…”